Abstract | BACKGROUND: METHODS: The records of all women presenting between January 1973 and December 1991 with a stage IIIB (T4d, any N, MO) breast cancer with proven dermal lymphatic invasion by tumor cells were reviewed retrospectively. RESULTS: The study comprised 38 women; 28 received CMF (22 CMF, 6 CMF/VP), and 10 received FAC. The overall response rate to induction chemotherapy in the CMF/VP group was 57% (40% PR, 17% CR), and 100% (60% PR, 40% CR) in the FAC group. The median overall survival for women receiving CMF/VP was 18 months compared with 30 months for women receiving FAC (p = 0.02). The median disease-free survivals for the CMF/VP and FAC groups were 6 and 24 months, respectively (p < 0.001). When comparing responders and nonresponders with CMF/VP induction therapy, the responders had a significantly longer overall median survival (24 versus 10 months) (p < 0.001) and disease-free median survival (8 versus 2 months) (p < 0.001). All of the five patients remaining alive received FAC with 80% (four of five) having a complete response. These four patients subsequently underwent mastectomy and radiation. CONCLUSION: This study suggests that a doxorubicin-containing chemotherapy regimen improves overall and disease-free median survivals when compared with the previously used CMF combination in the treatment of IBC. A favorable response to induction chemotherapy also appeared to be associated with an improved survival.
|
Authors | R L Bauer, E Busch, E Levine, S B Edge |
Journal | Annals of surgical oncology
(Ann Surg Oncol)
Vol. 2
Issue 4
Pg. 288-94
(Jul 1995)
ISSN: 1068-9265 [Print] United States |
PMID | 7552616
(Publication Type: Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Biopsy
- Breast Neoplasms
(drug therapy, mortality, pathology)
- Disease-Free Survival
- Doxorubicin
(therapeutic use)
- Female
- Humans
- Inflammation
(drug therapy, mortality, pathology)
- Middle Aged
- Retrospective Studies
- Survival Rate
|